Dicot AB (publ) ("Dicot" or the "Company") has conducted a rights issue of approximately SEK 21.8 million (the "Rights Issue"). The Rights Issue was subscribed with 326 percent. In total, 5,453,576 units were issued in the Rights Issue consisting of 21,814,304 shares and 21,814,304 warrants of series 2021 (TO2).
The Rights Issue has now been registered with the Swedish Companies Registration Office. The last day of trading in paid subscribed units (BTU) is July 6, 2020. The record day for conversion is July 8, 2020, after which BTU will be converted to shares and warrants of series 2021.
Shares and warrants issued in the Rights Issue are estimated to be available on subscribers' custody/vp-accounts on July 10, 2020.
The first day of trading in warrants of series 2021 is estimated to be July 10, 2020.
The warrants of series 2021 that have been issued through the Rights Issue entitle the holder to subscribe for one (1) new share in Dicot during the subscription period from March 17, 2021 through March 31, 2021. The subscription price for shares using the warrants will correspond to 70 percent of the volume weighted average price of the Company's shares according to the Spotlight Stock Market official price list for the period from March 1, 2021 through March 15, 2021 but will not be higher than SEK 2.00 or less than SEK 0.125 (corresponding to the quota value of the Company's shares).
Following the Rights Issue, the Company has 38,175,032 shares and the Company's share capital is SEK 4,771,879.
ISIN-code for shares in Dicot: SE0011178458
ISIN-code for BTU in Dicot: SE0014429411
ISIN-code for TO2 in Dicot: SE0014429379
Mangold Fondkommission AB is acting as financial adviser to the Company in the Rights Issue. Advokatfirman Lindahl KB is acting as the legal adviser to the Company.
For further information, please contact:
About Dicot AB
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, Libiguin™, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. For more information see www.dicot.se.
This press release is not an offer to subscribe for shares or units in Dicot and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in Dicot will only be made through the EU growth prospectus.
This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or in any other country where the Rights Issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a further prospectus is established, registered or that any other measure is undertaken beyond that required by Swedish law where such action as a whole or in part is subject to legal restrictions.
Neither unit rights, units subscribed for ("BTU") or newly issued units have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTA or newly issued shares have been registered or will be registered under the United States Securities Act of 1933, or under the securities law of any state in the United States. Therefore, no new shares, paid subscribed shares, subscription rights or other securities issued by the Company may be transferred, exercised or offered for sale in the United States other than in such exceptional cases that do not require registration or through a transaction that is not covered by such registration. There is no intention to register any portion of the offer in the United States and the securities issued in the Rights Issue will not be offered to the public in the United States.
The Company has not authorized any offer to the public with regards to the shares or rights that are referred to in this communication in any member state of the European Economic Area (''EEA'') besides Sweden. This communication is only addressed to and is only directed at qualified investors in other members states within the EEA member state and in the United Kingdom.